Figure 2. Anti-CCL22 treatment dampened the development and progression of EAE.
Mice were immunized with PLP139–151 in CFA at Day 0 and treated with normal goat Ig or polyclonal anti-murine CCL22 at Days –2 and 0 relative to immunization. (A) Anti-CCL22 treatment significantly (*P<0.05) inhibited acute and relapsing clinical disease. The data represent the mean clinical disease score at each specific day postimmunization. (B) In the same experiment, mean cumulative clinical score (±sd) was calculated, and there was a significant (*P<0.05) reduction in the anti-CCL22-treated group. (C) The mean number of relapses (±sd) was calculated for each group, and there was a significant (*P<0.05) reduction in the anti-CCL22-treated mice. The clinical results are representative of three independent experiments. (D) Anti-CCL22 treatment at Day +10, relative to disease induction, did not significantly inhibit acute clinical disease. The data represent the mean clinical disease score at each specific day postimmunization.